Epigenetic mechanisms in gastric cancer

Epigenomics

Volumn 4, Issue 3, 2012, Pages 279-294

  Gigek, Carolina Oliveira ^a   Chen, Elizabeth Suchi ^a   Calcagno, Danielle Queiroz ^a   Wisnieski, Fernanda ^a   Burbano, Rommel Rodriguez ^b   Smith, Marilia Arruda Cardoso ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF PARÁ   (Brazil)

Author keywords

chromatin remodeling complex; DNA methylation; epigenetics; gastric cancer; histone acetylation; histone methylation; hypermethylation; miRNA; phosphorylation

Indexed keywords

AZACITIDINE; BIOLOGICAL MARKER; BRG1 PROTEIN; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3A; HISTONE ACETYLTRANSFERASE; HISTONE ACETYLTRANSFERASE PCAF; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 8; HISTONE H3; MICRORNA; MICRORNA 101; MICRORNA 10B; MICRORNA 16; MICRORNA 182; MICRORNA 192; MICRORNA 200; MICRORNA 29A; MICRORNA 34B; MICRORNA 375; MICRORNA 9; PROTEIN HBO1; PROTEIN SWI; PROTEIN TIP60; SIRTUIN 1; TRANSCRIPTION FACTOR SNF; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AGING; CANCER GENETICS; CANCER INCIDENCE; CANCER PROGNOSIS; CHROMATIN ASSEMBLY AND DISASSEMBLY; CPG ISLAND; DNA METHYLATION; DRUG MECHANISM; EPIGENETICS; GENE EXPRESSION REGULATION; GENE MAPPING; GENETIC CODE; HISTONE METHYLATION; HISTONE MODIFICATION; HISTONE PHOSPHORYLATION; HISTONE UBIQUITINATION; HUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN TARGETING; REVIEW; STOMACH CANCER; STOMACH CARCINOGENESIS; SUMOYLATION; TUMOR SUPPRESSOR GENE;

AGE FACTORS; CELL TRANSFORMATION, NEOPLASTIC; CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA METHYLATION; EPIGENESIS, GENETIC; EPIGENOMICS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HISTONES; HUMANS; MICRORNAS; PROTEIN PROCESSING, POST-TRANSLATIONAL; STOMACH NEOPLASMS;

EID: 84862246467     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.12.22     Document Type: Review

References (151)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 61(2), 69-90 (2011).
2. Saif MW, Makrilia N, Zalonis A, Merikas M, Syrigos K. Gastric cancer in the elderly: an overview. Eur. J. Surg. Oncol. 36(8), 709-717 (2010).
3. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer Incidence in Five Continents. International Agency for Research on Cancer, Lyon, France (2002).
4. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J. Gastroenterol. 12(3), 354-362 (2006).
5. Laurén P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta. Pathol. Microbiol. Scand. 64, 31-49 (1965).
6. Yamashita S, Wakazono K, Sugimura T, Ushijima T. Profiling and selection of genes differentially expressed in the pylorus of rat strains with different proliferative responses and stomach cancer susceptibility. Carcinogenesis 23(6), 923-928 (2002).
7. Inca: Estimativas 2010: Incidência de Câncer no Brasil. Instituto Nacional de Câncer, Rio de Janeiro, Brazil (2010).
8. Shi Y, Zhou Y. The role of surgery in the treatment of gastric cancer. J. Surg. Oncol. 101(8), 687-692 (2010).
9. Assumpção PP, Burbano RR. Genética e câncer gástrico. In: Atualização em Câncer-Gástrico. Linhares E, Laércio L, Takeshi S (Eds). Tecmed, São Paulo, Brazil, 95-106 (2005).
10. Boveri T, Boveri M. The Origin of Malignant Tumors. Williams and Wilkins, MD, USA (1929).
11. Khayat AS, Guimaraes AC, Calcagno DQ et al. Interrelationship between TP53 gene deletion, protein expression and chromosome 17 aneusomy in gastric adenocarcinoma. BMC Gastroenterol. 9, 55 (2009).
12. Calcagno DQ, Leal MF, Taken SS et al. Aneuploidy of chromosome 8 and C-MYC amplification in individuals from northern Brazil with gastric adenocarcinoma. Anticancer Res. 25(6B), 4069-4074 (2005).
13. Burbano RR, Assumpcao PP, Leal MF et al. C-MYC locus amplification as metastasis predictor in intestinal-type gastric adenocarcinomas: CGH study in Brazil. Anticancer Res. 26(4B), 2909-2914 (2006).
14. Assumpcao PP, Ishak G, Chen ES et al. Numerical aberrations of chromosome 8 detected by conventional cytogenetics and fluorescence in situ hybridization in individuals from northern Brazil with gastric adenocarcinoma. Cancer Genet. Cytogenet. 169(1), 45-49 (2006).
15. Calcagno DQ, Guimaraes AC, Leal MF et al. MYC insertions in diffuse-type gastric adenocarcinoma. Anticancer Res. 29(7), 2479-2483 (2009).
16. Borges Bdo N, Burbano RR, Harada ML. Survivin -31C/G polymorphism and gastric cancer risk in a Brazilian population. Clin. Exp. Med. 11(3), 189-193 (2011).
17. Lima EM, Araujo JJ, Harada ML, Assumpcao PP, Burbano RR, Casartelli C. Molecular study of the tumour suppressor gene PTEN in gastric adenocarcinoma in Brazil. Clin. Exp. Med. 5(3), 129-132 (2005).
18. Khayat AS, Lobo Gatti L, Moura Lima E et al. Polymorphisms of the TP53 codon 72 and WRN codon 1367 in individuals from northern Brazil with gastric adenocarcinoma. Clin. Exp. Med. 5(4), 161-168 (2005).
19. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat. Rev. Genet. 7(1), 21-33 (2006).
20. Waddington CH. The epigenotype. Endeavour 1, 18-20 (1942). and stomach cancer susceptibility. Carcinogenesis 23(6), 923-928 (2002).
21. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis 31(1), 27-36 (2010). A very comprehensive review about overall epigenetic mechanisms in normal and cancer cells.
22. Deangelis JT, Farrington WJ, Tollefsbol TO. An overview of epigenetic assays. Mol. Biotechnol. 38(2), 179-183 (2008).
23. Portela A, Esteller M. Epigenetic modifications and human disease. Nat. Biotechnol. 28(10), 1057-1068 (2010). Excellent and well-written review about all types of epigenetic modifications and the abnormal epimarkers in disease, such as cancer and neurodevelopmental, neurodegenerative and autoimmune disorders.
24. Deaton AM, Bird A. CpG islands and the regulation of transcription. Genes Dev. 25(10), 1010-1022 (2011).
25. Taby R, Issa JP. Cancer epigenetics. CA Cancer J. Clin. 60(6), 376-392 (2010). Clinical applications of epigenetic tumor markers drugs and therapy in cancer.
26. Fan H, Liu D, Qiu X et al. A functional polymorphism in the DNA methyltransferase-3A promoter modifies the susceptibility in gastric cancer but not in esophageal carcinoma. BMC Med. 8, 12 (2010).
27. Hu J, Fan H, Liu D, Zhang S, Zhang F, Xu H. DNMT3B promoter polymorphism and risk of gastric cancer. Dig. Dis. Sci. 55(4), 1011-1016 (2010).
28. Yang J, Wei X, Wu Q et al. Clinical significance of the expression of DNA methyltransferase proteins in gastric cancer. Mol. Med. Report 4(6), 1139-1143 (2011).
29. Mutze K, Langer R, Becker K et al. Histone deacetylase (HDAC) 1 and 2 expression and chemotherapy in gastric cancer. Ann. Surg. Oncol. 17(12), 3336-3343 (2010).
30. Kanai Y, Ushijima S, Kondo Y, Nakanishi Y, Hirohashi S. DNA methyltransferase expression and DNA methylation of CPG islands and peri-centromeric satellite regions in human colorectal and stomach cancers. Int. J. Cancer 91(2), 205-212 (2001).
31. Yan J, Zhang M, Zhang J, Chen X, Zhang X. Helicobacter pylori infection promotes methylation of WWOX gene in human gastric cancer. Biochem. Biophys. Res. Commun. 408(1), 99-102 (2011).
32. Oue N, Kuraoka K, Kuniyasu H et al. DNA methylation status of hMLH1, p16(INK4a), and CDH1 is not associated with mRNA expression levels of DNA methyltransferase and DNA demethylase in gastric carcinomas. Oncol. Rep. 8(5), 1085-1089 (2001).
33. Selaru FM, David S, Meltzer SJ, Hamilton JP. Epigenetic events in gastrointestinal cancer. Am. J. Gastroenterol. 104(8), 1910-1912 (2009).
34. Baylin SB, Jones PA. A decade of exploring the cancer epigenome - biological and translational implications. Nat. Rev. Cancer 11(10), 726-734 (2011).
35. Ding SZ, Goldberg JB, Hatakeyama M. Helicobacter pylori infection, oncogenic pathways and epigenetic mechanisms in gastric carcinogenesis. Future Oncol. 6(5), 851-862 (2010). Very important to gastric carcinogenesis, this review provides a Helicobacter pylori overview about pathogenicity mechanisms and pathways via epigenetic alterations.
36. Calcagno DQ, Gigek CO, Chen ES, Burbano RR, Smith MAC. DNA and histone methylation in gastric carcinogenesis. World J. Gastroenterol. (2012) (In Press). A recent review that provides extensive information about DNA and histone methylation machinery and alterations in gastric cancer
37. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 21(35), 5427-5440 (2002).
38. Hu XT, He C. Recent progress in the study of methylated tumor suppressor genes in gastric cancer. Chin. J. Cancer doi:10.5732/cjc.011.10175 (2011) (Epub ahead of print). A detailed description of several hypermethylated tumor-suppressor genes previously described in gastric cancer.
39. Shin CM, Kim N, Park JH et al. Prediction of the risk for gastric cancer using candidate methylation markers in the non-neoplastic gastric mucosae. J. Pathol. 226(4), 654-665 (2012).
40. Ando T, Yoshida T, Enomoto S et al. DNA methylation of microRNA genes in gastric mucosae of gastric cancer patients: its possible involvement in the formation of epigenetic field defect. Int. J. Cancer 124(10), 2367-2374 (2009).
41. Gigek CO, Leal MF, Lisboa LC et al. Insulin-like growth factor binding protein-3 gene methylation and protein expression in gastric adenocarcinoma. Growth Horm. IGF Res. 20(3), 234-238 (2010).
42. Leal MF, Lima EM, Silva PN et al. Promoter hypermethylation of CDH1, FHIT, TAP and PLAGL1 in gastric adenocarcinoma in individuals from northern Brazil. World J. Gastroenterol. 13(18), 2568-2574 (2007).
43. Stec-Michalska K, Peczek L, Michalski B, Wisniewska-Jarosinska M, Krakowiak A, Nawrot B. Helicobacter pylori infection and family history of gastric cancer decrease expression of FHIT tumor suppressor gene in gastric mucosa of dyspeptic patients. Helicobacter 14(5), 126-134 (2009).
44. Borges Bdo N, Santos Eda S, Bastos CE et al. Promoter polymorphisms and methylation of E-cadherin (CDH1) and KIT in gastric cancer patients from northern Brazil. Anticancer Res. 30(6), 2225-2233 (2010).
45. Irizarry RA, Ladd-Acosta C, Wen B et al. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat. Genet. 41(2), 178-186 (2009).
46. Illingworth RS, Gruenewald-Schneider U, Webb S et al. Orphan CpG islands identify numerous conserved promoters in the mammalian genome. PLoS Genet. 6(9), pii: e1001134 (2010).
47. Gigek CO, Leal MF, Silva PN et al. hTERT methylation and expression in gastric cancer. Biomarkers 14(8), 630-636 (2009).
48. Lima EM, Leal MF, Burbano RR et al. Methylation status of ANAPC1, CDKN2A and TP53 promoter genes in individuals with gastric cancer. Braz. J. Med. Biol. Res. 41(6), 539-543 (2008).
49. Alves MK, Lima VP, Ferrasi AC, Rodrigues MA, De Moura Campos Pardini MI, Rabenhorst SH. CDKN2A promoter methylation is related to the tumor location and histological subtype and associated with Helicobacter pylori flaA(+) strains in gastric adenocarcinomas. APMIS 118(4), 297-307 (2010).
50. Cao Z, Yoon JH, Nam SW, Lee JY, Park WS. PDCD4 expression inversely correlated with miR-21 levels in gastric cancers. J. Cancer Res. Clin. Oncol. 138(4), 611-619 (2012).
51. Zheng Y, Chen L, Li J et al. Hypermethylated DNA as potential biomarkers for gastric cancer diagnosis. Clin. Biochem. 44(17-18), 1405-1411 (2011).
52. Jee CD, Kim MA, Jung EJ, Kim J, Kim WH. Identification of genes epigenetically silenced by CpG methylation in human gastric carcinoma. Eur. J. Cancer 45(7), 1282-1293 (2009).
53. Dong W, Wang L, Chen X, Sun P, Wu Y. Upregulation and CpG island hypomethylation of the TRF2 gene in human gastric cancer. Dig. Dis. Sci. 55(4), 997-1003 (2010).
54. Wang X, Fan J, Liu D, Fu S, Ingvarsson S, Chen H. Spreading of Alu methylation to the promoter of the MLH1 gene in gastrointestinal cancer. PLoS ONE 6(10), e25913 (2011).
55. Abbaszadegan MR, Moaven O, Sima HR et al. p16 promoter hypermethylation: a useful serum marker for early detection of gastric cancer. World J. Gastroenterol. 14(13), 2055-2060 (2008).
56. Ikoma H, Ichikawa D, Daito I et al. Clinical application of methylation specific-polymerase chain reaction in serum of patients with gastric cancer. Hepatogastroenterology 54(75), 946-950 (2007).
57. Wang YC, Yu ZH, Liu C et al. Detection of RASSF1A promoter hypermethylation in serum from gastric and colorectal adenocarcinoma patients. World J. Gastroenterol. 14(19), 3074-3080 (2008).
58. Chen L, Su L, Li J et al. Hypermethylated FAM5C and MYLK in serum as diagnosis and pre-warning markers for gastric cancer. Dis. Markers 32(3), 195-202 (2012).
59. Hibi K, Goto T, Shirahata A et al. Detection of TFPI2 methylation in the serum of gastric cancer patients. Anticancer Res. 31(11), 3835-3838 (2011).
60. Bernal C, Aguayo F, Villarroel C et al. Reprimo as a potential biomarker for early detection in gastric cancer. Clin. Cancer Res. 14(19), 6264-6269 (2008).
61. Zheng Y, Zhang Y, Huang X, Chen L. Analysis of the RUNX3 gene methylation in serum DNA from esophagus squamous cell carcinoma, gastric and colorectal adenocarcinoma patients. Hepatogastroenterology 58(112), 2007-2011 (2011).
62. Collas P. The state-of-the-art of chromatin immunoprecipitation. Methods Mol. Biol. 567, 1-25 (2009).
63. Kouzarides T, Berger S. Chromatin modifications and their mechanism of action. In: Epigenetics. Allis CD, Jenuwein T, Reinberg D (Eds). Cold Spring Harbor Laboratory Press, NY, USA 191-209 (2009).
64. Kanwal R, Gupta S. Epigenetic modifications in cancer. Clin. Genet. 81(4), 303-311 (2012). Recent review about miRNA and histone modifications in cancer.
65. Liu C, Xu D. Inhibition of histone deacetylases. In: Epigenetics Protocol. Tollefsbol TO (Ed.). Human Press Inc., NJ, USA, 87-97 (2010). Outlines epigenetic basic theories and protocols for researchers.
66. Ellis L, Atadja PW, Johnstone RW. Epigenetics in cancer: targeting chromatin modifications. Mol. Cancer Ther. 8(6), 1409-1420 (2009).
67. Glozak MA, Sengupta N, Zhang X, Seto E. Acetylation and deacetylation of non-histone proteins. Gene 363, 15-23 (2005).
68. Davis PK, Brackmann RK. Chromatin remodeling and cancer. Cancer Biol. Ther. 2(1), 22-29 (2003).
69. Kouzarides T. Chromatin modifications and their function. Cell 128(4), 693-705 (2007).
70. Ferrari R, Pellegrini M, Horwitz GA, Xie W, Berk AJ, Kurdistani SK. Epigenetic reprogramming by adenovirus e1a. Science 321(5892), 1086-1088 (2008).
71. Horwitz GA, Zhang K, Mcbrian MA, Grunstein M, Kurdistani SK, Berk AJ. Adenovirus small e1a alters global patterns of histone modification. Science 321(5892), 1084-1085 (2008).
72. Koshiishi N, Chong JM, Fukasawa T et al. p300 gene alterations in intestinal and diffuse types of gastric carcinoma. Gastric Cancer 7(2), 85-90 (2004).
73. Ying MZ, Wang JJ, Li DW et al. The p300/CBP associated factor: is frequently downregulated in intestinal-type gastric carcinoma and constitutes a biomarker for clinical outcome. Cancer Biol. Ther. 9(4), 312-320 (2010).
74. Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene 26(37), 5420-5432 (2007).
75. Mohamed MA, Greif PA, Diamond J et al. Epigenetic events, remodelling enzymes and their relationship to chromatin organization in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. BJU Int. 99(4), 908-915 (2007).
76. Song J, Noh JH, Lee JH et al. Increased expression of histone deacetylase 2 is found in human gastric cancer. APMIS 113(4), 264-268 (2005).
77. Liu T, Kuljaca S, Tee A, Marshall GM. Histone deacetylase inhibitors: multifunctional anticancer agents. Cancer Treat. Rev. 32(3), 157-165 (2006).
78. Thiagalingam S, Cheng KH, Lee HJ, Mineva N, Thiagalingam A, Ponte JF. Histone deacetylases: unique players in shaping the epigenetic histone code. Ann. NY Acad. Sci. 983, 84-100 (2003).
79. Wu ZQ, Zhang R, Chao C, Zhang JF, Zhang YQ. Histone deacetylase inhibitor trichostatin A induced caspase-independent apoptosis in human gastric cancer cell. Chin. Med. J. (Engl.) 120(23), 2112-2118 (2007).
80. Zou XM, Li YL, Wang H et al. Gastric cancer cell lines induced by trichostatin A. World J. Gastroenterol. 14(30), 4810-4815 (2008).
81. Ye Y, Xiao Y, Wang W et al. Inhibition of expression of the chromatin remodeling gene, SNF2L, selectively leads to DNA damage, growth inhibition, and cancer cell death. Mol. Cancer Res. 7(12), 1984-1999 (2009).
82. Gigek CO, Lisboa LC, Leal MF et al. SMARCA5 methylation and expression in gastric cancer. Cancer Invest. 29(2), 162-166 (2011).
83. Lee JH, Song MY, Song EK et al. Overexpression of SIRT1 protects pancreatic b-cells against cytokine toxicity by suppressing the nuclear factor-kB signaling pathway. Diabetes 58(2), 344-351 (2009).
84. Saunders LR, Verdin E. Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene 26(37), 5489-5504 (2007).
85. Aihara T, Miyoshi Y, Koyama K et al. Cloning and mapping of SMARCA5 encoding hSNF2H, a novel human homologue of Drosophila ISWI. Cytogenetics Cell Genetics 81(3-4), 191-193 (1998).
86. Cha EJ, Noh SJ, Kwon KS et al. Expression DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma. Clin. Cancer Res. 15(13), 4453-4459 (2009).
87. Fraga MF, Ballestar E, Villar-Garea A et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet. 37(4), 391-400 (2005).
88. Mitani Y, Oue N, Hamai Y et al. Histone H3 acetylation is associated with reduced p21 (WAF1/CIP1) expression by gastric carcinoma. J. Pathol. 205(1), 65-73 (2005).
89. Song IS, Ha GH, Kim JM et al. Human ZNF312b oncogene is regulated by Sp1 binding to its promoter region through DNA demethylation and histone acetylation in gastric cancer. Int. J. Cancer 129(9), 2124-2133 (2011).
90. Wang XH, Zhang LH, Zhong XY et al. S100A6 overexpression is associated with poor prognosis and is epigenetically up-regulated in gastric cancer. Am. J. Pathol. 177(2), 586-597 (2010).
91. Ono S, Oue N, Kuniyasu H et al. Acetylated histone H4 is reduced in human gastric adenomas and carcinomas. J. Exp. Clin. Cancer Res. 21(3), 377-382 (2002).
92. Yasui W, Oue N, Ono S, Mitani Y, Ito R, Nakayama H. Histone acetylation and gastrointestinal carcinogenesis. Ann. NY Acad. Sci. 983, 220-231 (2003).
93. Shilatifard A. Chromatin modifications by methylation and ubiquitination: implications in the regulation of gene expression. Annu. Rev. Biochem. 75, 243-269 (2006).
94. Richards EJ, Elgin SC. Epigenetic codes for heterochromatin formation and silencing: rounding up the usual suspects. Cell 108(4), 489-500 (2002).
95. Lan F, Shi Y. Epigenetic regulation: methylation of histone and non-histone proteins. Sci. China 52(4), 311-322 (2009).
96. Zhang BG, Li JF, Yu BQ, Zhu ZG, Liu BY, Yan M. microRNA-21 promotes tumor proliferation and invasion in gastric cancer by targeting PTEN. Oncol. Rep. 27(4), 1019-1026 (2012).
97. Park YS, Jin MY, Kim YJ, Yook JH, Kim BS, Jang SJ. The global histone modification pattern correlates with cancer recurrence and overall survival in gastric adenocarcinoma. Ann. Surg. Oncol. 15(7), 1968-1976 (2008).
98. Kwon MJ, Kim SH, Jeong HM et al. Claudin-4 overexpression is associated with epigenetic depression in gastric carcinoma. Lab. Invest. 91(11), 1652-1667 (2011).
99. Kwon OH, Park JL, Kim M et al. Aberrant up-regulation of LAMB3 and LAMC2 by promoter demethylation in gastric cancer. Biochem. Biophys. Res. Commun. 406(4), 539-545 (2011).
100. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat. Rev. Genet. 8(4), 286-298 (2007).
101. Varambally S, Cao Q, Mani RS et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 322(5908), 1695-1699 (2008).
102. Fujii S, Ochiai A. Enhancer of zeste homolog 2 downregulates E-cadherin by mediating histone H3 methylation in gastric cancer cells. Cancer Sci. 99(4), 738-746 (2008).
103. Meng CF, Zhu XJ, Peng G, Dai DQ. Re-expression of methylation-induced tumor suppressor gene silencing is associated with the state of histone modification in gastric cancer cell lines. World J. Gastroenterol. 13(46), 6166-6171 (2007).
104. Meng CF, Zhu XJ, Peng G, Dai DQ. Promoter histone H3 lysine 9 di-methylation is associated with DNA methylation and aberrant expression of p16 in gastric cancer cells. Oncol. Reports 22(5), 1221-1227 (2009).
105. Takahashi H, Murai Y, Tsuneyama K et al. Overexpression of phosphorylated histone H3 is an indicator of poor prognosis in gastric adenocarcinoma patients. Appl. Immunohistochem. Mol. Morphol. 14(3), 296-302 (2006).
106. Henry KW, Wyce A, Lo WS et al. Transcriptional activation via sequential histone H2B ubiquitylation and deubiquitylation, mediated by SAGA-associated Ubp8. Genes Dev. 17(21), 2648-2663 (2003).
107. Shiio Y, Eisenman RN. Histone sumoylation is associated with transcriptional repression. Proc. Natl Acad. Sci. USA 100(23), 13225-13230 (2003).
108. Ho L, Crabtree GR. Chromatin remodelling during development. Nature 463(7280), 474-484 (2010).
109. Tsukiyama T, Daniel C, Tamkun J, Wu C. ISWI, a member of the SWI2/SNF2 ATPase family, encodes the 140 kDa subunit of the nucleosome remodeling factor. Cell 83(6), 1021-1026 (1995).
110. Varga-Weisz PD, Wilm M, Bonte E, Dumas K, Mann M, Becker PB. Chromatinremodelling factor CHRAC contains the ATPases ISWI and topoisomerase II. Nature 388(6642), 598-602 (1997).
111. Wilson BG, Roberts CW. SWI/SNF nucleosome remodellers and cancer. Nat. Rev. Cancer 11(7), 481-492 (2011).
112. Jones S, Li M, Parsons DW et al. Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum. Mutat. 33(1), 100-103 (2012).
113. Wang K, Kan J, Yuen St et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat. Genet. 43(12), 1219-1223 (2011).
114. Sentani K, Oue N, Kondo H et al. Increased expression but not genetic alteration of BRG1, a component of the SWI/SNF complex, is associated with the advanced stage of human gastric carcinomas. Pathobiology 69(6), 315-320 (2001).
115. Yamamichi N, Inada K, Ichinose M et al. Frequent loss of Brm expression in gastric cancer correlates with histologic features and differentiation state. Cancer Res. 67(22), 10727-10735 (2007).
116. Esteller M. Non-coding RNAs in human disease. Nat. Rev. Genet. 12(12), 861-874 (2011).
117. Rotkrua P, Akiyama Y, Hashimoto Y, Otsubo T, Yuasa Y. MiR-9 downregulates CDX2 expression in gastric cancer cells. Int. J. Cancer 129(11), 2611-2620 (2011).
118. Song B, Ju J. Impact of miRNAs in gastrointestinal cancer diagnosis and prognosis. Expert Rev. Mol. Med. 12, E33 (2010). Covers the results of miRNA research in gastric and other gastrointestinal cancers until 2010.
119. Liu H, Zhu L, Liu B et al. Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer. Cancer Lett. 316(2), 196-203 (2012).
120. Liu R, Zhang C, Hu Z et al. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur. J. Cancer 47(5), 784-791 (2011).
121. Tsujiura M, Ichikawa D, Komatsu S et al. Circulating microRNAs in plasma of patients with gastric cancers. Br. J. Cancer 102(7), 1174-1179 (2010).
122. Li X, Luo F, Li Q et al. Identification of new aberrantly expressed miRNAs in intestinal-type gastric cancer and its clinical significance. Oncol. Rep. 26(6), 1431-1439 (2011).
123. Nakagawa M, Oda Y, Eguchi T et al. Expression profile of class I histone deacetylases in human cancer tissues. Oncol. Rep. 18(4), 769-774 (2007).
124. Feng AN, Zhang LH, Fan XS et al. Expression of SIRT1 in gastric cardiac cancer and its clinicopathologic significance. Int. J. Surg. Pathol. 19(6), 743-750 (2011).
125. Sakuraba K, Yokomizo K, Shirahata A et al. TIP60 as a potential marker for the malignancy of gastric cancer. Anticancer Res. 31(1), 77-79 (2011).
126. Iizuka M, Takahashi Y, Mizzen CA et al. Histone acetyltransferase Hbo1: catalytic activity, cellular abundance, and links to primary cancers. Gene 436(1-2), 108-114 (2009).
127. Guo X, Jing C, Li L et al. Down-regulation of VEZT gene expression in human gastric cancer involves promoter methylation and miR-43c. Biochem. Biophys. Res. Commun. 404(2), 622-627 (2011).
128. Chiang Y, Zhou X, Wang Z et al.: Expression levels of microRNA-192 and -215 in gastric carcinoma. Pathol. Oncol. Res. (2011).
129. Furuta M, Kozaki KI, Tanaka S, Arii S, Imoto I, Inazawa J. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis 31(5), 766-776 (2010).
130. Chiang Y, Song Y, Wang Z et al. Aberrant expression of miR-203 and its clinical significance in gastric and colorectal cancers. J. Gastrointest. Surg. 15(1), 63-70 (2011).
131. Sun T, Wang C, Xing J, Wu D. miR-429 modulates the expression of c-myc in human gastric carcinoma cells. Eur. J. Cancer 47(17), 2552-2559 (2011).
132. Xu L, Wang F, Xu XF et al. Down-regulation of miR-212 expression by DNA hypermethylation in human gastric cancer cells. Med. Oncol. 28(Suppl. 1), S189-S196 (2011).
133. Wang HJ, Ruan HJ, He XJ et al. MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration and invasion. Eur. J. Cancer 46(12), 2295-2303 (2010).
134. Zhu A, Xia J, Zuo J et al. MicroRNA-148a silenced by hypermethylation and interacts with DNA methyltransferase 1 in gastric cancer. Med. Oncol. doi:10.1007/s12032-011-0134-3 (2011) (Epub ahead of print).
135. Song YX, Yue ZY, Wang ZN et al. MicroRNA-148b is frequently down-regulated in gastric cancer and acts as a tumor suppressor by inhibiting cell proliferation. Mol. Cancer 10, 1 (2011).
136. Tsai KW, Wu CW, Hu LY et al. Epigenetic regulation of miR-34b and miR-129 expression in gastric cancer. Int. J. Cancer 129(11), 2600-2610 (2011).
137. Bou Kheir T, Futoma-Kazmierczak E, Jacobsen A et al. miR-449 inhibits cell proliferation and is down-regulated in gastric cancer. Mol. Cancer 10, 29 (2011).
138. Ahn SM, Cha JY, Kim J et al. Smad3 regulates E-cadherin via miRNA-200 pathway. Oncogene doi:10.1038/onc.2011.484 (2011) (Epub ahead of print).
139. Kong WQ, Bai R, Liu T et al. MicroRNA-182 targets cyclic adenosine monophosphate responsive element binding protein 1 (CREB1) and suppresses cell growth in human gastric adenocarcinoma. FEBS J. 279(7), 1252-1260 (2012).
140. Kong D, Piao YS, Yamashita S et al. Inflammation-induced repression of tumor suppressor miR-7 in gastric tumor cells. Oncogene (2011).
141. Cui Y, Su WY, Xing J et al. MiR-29a inhibits cell proliferation and induces cell cycle arrest through the downregulation of p42.3 in human gastric cancer. PLoS ONE 6(10), e25872 (2011).
142. Hashiguchi Y, Nishida N, Mimori K et al. Down-regulation of miR-125a-3p in human gastric cancer and its clinicopathological significance. Int. J. Oncol. 40(5), 1477-1482 (2012).
143. Nishida N, Mimori K, Fabbri M et al. MicroRNA-125a-5p is an independent prognostic factor in gastric cancer and inhibits the proliferation of human gastric cancer cells in combination with trastuzumab. Clin. Cancer Res. 17(9), 2725-2733 (2011).
144. Tsukamoto Y, Nakada C, Noguchi T et al. MicroRNA-375 is downregulated in gastric carcinomas and regulates cell survival by targeting PDK1 and 14-3-3zeta. Cancer Res. 70(6), 2339-2349 (2010).
145. Ohshima K, Inoue K, Fujiwara A et al. Let-7 microRNA family is selectively secreted into the extracellular environment via exosomes in a metastatic gastric cancer cell line. PLoS ONE 5(10), e13247 (2011).
146. Shin VY, Jin H, Ng EK et al. NF-κB targets miR-16 and miR-21 in gastric cancer: involvement of prostaglandin E receptors. Carcinogenesis 32(2), 240-245 (2010).
147. Chan SH, Wu CW, Li AF, Chi CW, Lin WC. miR-21 microRNA expression in human gastric carcinomas and its clinical association. Anticancer Res. 28(2A), 907-911 (2008).
148. Jin Z, Selaru FM, Cheng Y et al. MicroRNA-192 and -215 are upregulated in human gastric cancer in vivo and suppress ALCAM expression in vitro. Oncogene 30(13), 1577-1585 (2011).
149. Otsubo T, Akiyama Y, Hashimoto Y, Shimada S, Goto K, Yuasa Y. MicroRNA-126 inhibits SOX2 expression and contributes to gastric carcinogenesis. PLoS ONE 6(1), e16617 (2011).
150. Xiao B, Zhu ED, Li N et al. Increased miR-146a in gastric cancer directly targets SMAD4 and is involved in modulating cell proliferation and apoptosis. Oncol. Rep. 27(2), 559-566 (2012).
151. Brenner B, Hoshen MB, Purim O et al. MicroRNAs as a potential prognostic factor in gastric cancer. World J. Gastroenterol. 17(35), 3976-3985 (2011).